Serum angiotensin-converting enzyme level for evaluating significant fibrosis in chronic hepatitis B

Table 1 The clinicopathological characteristics of the patients with hepatitis B

Variables	Patients with HB (n = 70)
Sex (males/females)	37/33
Age	48.6 ± 14.1
Fibrosis stage (F0/F1/F2/F3/F4)	9/25/17/13/6
Platelet (× 104 μL) (F0/F1/F2/F3/F4)	17.9 ± 5.0 (23.2 ± 4.7/18.4 ± 3.6/18.7 ± 3.8/15.1 ± 5.4/18.9 ± 3.3)
Alb (g/dL)	4.1 ± 0.4
AST (IU/L)	35.8 ± 26.7
ALT (IU/L)	42.6 ± 39.4
HBV DNA (Log IU/mL)	4.04 ± 2.24
HBsAg (IU/mL)	22697.1 ± 52927.9
Hyaluronic acid (ng/mL)	62.4 ± 92.1
Type 4 collagen 7S (ng/mL)	4.1 ± 2.0
Serum ACE (U/L) (F0/F1/F2/F3/F4)	14.1 ± 5.1 (10.8 ± 2.3/11.1 ± 4.7/17.9 ± 4.4/6.4 ± 3.9/15.0 ± 2.9)
APRI (F0/F1/F2/F3/F4)	1.0 ± 1.3 (0.3 ± 0.1/0.7 ± 0.5/0.9 ± 0.6/2.3 ± 2.1/1.0 ± 0.9)
FIB4 (F0/F1/F2/F3/F4)	2.0 ± 1.9 (1.3 ± 0.6/1.6 ± 1.0/1.3 ± 0.8/2.8 ± 1.7/1.7 ± 0.7)
M2BPGi (COI) (F0/F1/F2/F3/F4)	1.2 ± 1.1 (0.9 ± 0.9/0.9 ± 0.6/.1 ± 1.0/2.2 ± 1.8/1.3 ± 0.6)

HBV: Hepatitis B virus; HBsAg: Hepatitis B surface antigen; Alb: Albumin; AST: Aspartate aminotransferase; ALT: Alanine aminotransferase; ACE: Angiotensin-I-converting enzyme; APRI: Aspartate aminotransferase-to-platelet index; FIB4: Fibrosis index based on four factors; M2BPGi: Mac-2-binding protein glycosylation isomer.